Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2021 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

SM Health Comm

Recent Posts

  • Commercialization Agreement for Bio-Thera’s Investigational Ustekinumab Biosimilar September 10, 2021
  • Pegfilgrastim Prefilled Syringe vs. On-Body Injector: Study Finds no Meaningful Differences in Clinical or Economic Outcomes September 7, 2021
  • What Is Important to the Public About Biosimilars? Think Like a Layperson August 25, 2021
  • Formycon and Bioeq Resubmit 351(k) Application August 10, 2021
  • Biden Administration Moves Away From the Most-Favored-Nation Drug Pricing Model August 9, 2021
  • Interchangeability Is Finally a Reality July 29, 2021
  • The FDA’s Aducanumab Affair and How It Relates to Biosimilars July 22, 2021
  • Amgen Crosses Biosimilar Misinformation Line, Says FDA July 16, 2021
  • An Update on Legislation on Biosimilars and Patents July 6, 2021
  • Enticing Patients to Switch to Infliximab Biosimilars June 25, 2021

Recent Comments

Commercialization Ag… on The Next-Generation Biosimilar…
How Can We Provide B… on Interchangeability Is Finally…
Formycon and Bioeq R… on Further Dissecting the Launch…
Formycon and Bioeq R… on Ophthalmology Biosimilars May…
Formycon and Bioeq R… on Biosimilar Company Updates: Ta…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Biosimilar Approval Status
  • Apotex/Apobiologix: Success in Canada, but Are They Shelving Biosimilars in the US?
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
  • Further Dissecting the Launch of Adalimumab Biosimilars in the US
  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • The Evolution of the Biosimilars Market
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
  • Amgen Settles With Alexion on Soliris Biosimilar, Dropping Litigation and Getting a Release Date
  • The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
  • Bevacizumab ASP Pricing now Dropping With Biosimilar Entries
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2021 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.